Literature DB >> 8629720

Genetic screening for reproductive planning: methodological and conceptual issues in policy analysis.

D A Asch1, J C Hershey, M V Pauly, J P Patton, M K Jedrziewski, M T Mennuti.   

Abstract

OBJECTIVES: This paper explores several critical assumptions and methodological issues arising in cost-effectiveness analyses of genetic screening strategies in the reproductive setting.
METHODS: Seven issues that arose in the development of a decision analysis of alternative strategies for cystic fibrosis carrier screening are discussed. Each of these issues required a choice in technique.
RESULTS: The presentations of these analyses frequently mask underlying assumptions and methodological choices. Often there is no best choice. In the case of genetic screening in the reproductive setting, these underlying issues often touch on deeply felt human values.
CONCLUSIONS: Space limitations for published papers often preclude explaining such choices in detail; yet these decisions determine the way the results should be interpreted. Those who develop these analyses need to make sure that the implications of important assumptions are understood by the clinicians who will use them. At the same time, clinicians need to enhance their understanding of what these models truly mean and how they address underlying clinical, ethical, and economic issues.

Entities:  

Keywords:  Genetics and Reproduction

Mesh:

Year:  1996        PMID: 8629720      PMCID: PMC1380477          DOI: 10.2105/ajph.86.5.684

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  19 in total

1.  Substituting diagnostic services. New tests only partly replace older ones.

Authors:  J M Eisenberg; J S Schwartz; F C McCaslin; R Kaufman; H Glick; E Kroch
Journal:  JAMA       Date:  1989-09-01       Impact factor: 56.272

2.  Costs and benefits of prenatal screening for cystic fibrosis.

Authors:  A M Garber; J P Fenerty
Journal:  Med Care       Date:  1991-05       Impact factor: 2.983

3.  Prenatal diagnosis of cystic fibrosis using linked DNA markers and microvillar intestinal enzyme analysis.

Authors:  J E Spence; G J Buffone; C L Rosenbloom; S D Fernbach; M R Curry; R J Carpenter; D H Ledbetter; W E O'Brien; A L Beaudet
Journal:  Hum Genet       Date:  1987-05       Impact factor: 4.132

4.  Clinical guidelines for using two dichotomous tests.

Authors:  J C Hershey; R D Cebul; S V Williams
Journal:  Med Decis Making       Date:  1986 Apr-Jun       Impact factor: 2.583

5.  Prenatal diagnosis of cystic fibrosis: microvillar enzymes and DNA analysis compared.

Authors:  G J Buffone; J E Spence; S D Fernbach; M R Curry; W E O'Brien; A L Beaudet
Journal:  Clin Chem       Date:  1988-05       Impact factor: 8.327

6.  Linkage disequilibrium, cystic fibrosis, and genetic counseling.

Authors:  A L Beaudet; G L Feldman; S D Fernbach; G J Buffone; W E O'Brien
Journal:  Am J Hum Genet       Date:  1989-03       Impact factor: 11.025

7.  Prenatal diagnosis of cystic fibrosis by microvillar enzyme assay on a sequence of 258 pregnancies.

Authors:  D J Brock; H A Clarke; L Barron
Journal:  Hum Genet       Date:  1988-03       Impact factor: 4.132

8.  The cost-effectiveness of prenatal carrier screening for cystic fibrosis.

Authors:  T A Lieu; S E Watson; A E Washington
Journal:  Obstet Gynecol       Date:  1994-12       Impact factor: 7.661

9.  A child with cystic fibrosis: II. Subsequent family planning decisions, reproduction and use of prenatal diagnosis.

Authors:  G Evers-Kiebooms; L Denayer; H Van den Berghe
Journal:  Clin Genet       Date:  1990-03       Impact factor: 4.438

10.  Knowing for the sake of knowing: the value of prognostic information.

Authors:  D A Asch; J P Patton; J C Hershey
Journal:  Med Decis Making       Date:  1990 Jan-Mar       Impact factor: 2.583

View more
  2 in total

1.  Prenatal screening for cystic fibrosis carriers: an economic evaluation.

Authors:  P T Rowley; S Loader; R M Kaplan
Journal:  Am J Hum Genet       Date:  1998-10       Impact factor: 11.025

Review 2.  Issues surrounding the health economic evaluation of genomic technologies.

Authors:  James Buchanan; Sarah Wordsworth; Anna Schuh
Journal:  Pharmacogenomics       Date:  2013-11       Impact factor: 2.533

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.